Natera, Inc.
NTRAHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeNatera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. At a $58.23B market cap, Natera, Inc. ranks as a large-cap company within healthcare. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Market Cap
$58.23B
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
-2271.42
EPS (TTM)
$-1.36
EPS (Fwd)
$-0.18
ROE
-12.5%
ROA
-8.1%
Cash
$1.09B
Total Debt
$238.5M
Free CF
$104.0M
52W Change
109.8%
Annual Financials
Cash vs Debt
Where NTRA stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, NTRA finished 52.23% above its 150-day moving average ($263.23) and 58.14% above its 200-day moving average ($253.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NTRA overbought or oversold?
At the October 12, 2026 close, NTRA's RSI(14) was 63.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.09B in cash comfortably exceeding the $238.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $104.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of -12.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $820.2M (2022) to $2.31B (2025), reflecting a 181% increase over the period.
With cash comfortably exceeding debt, NTRA has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing NTRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.